Kiora Pharmaceuticals Inc (KPRX): R&D Expense
$10.78M
Year ended 2025-12-31
$9.86M
Trailing 12 months to 2026-06-30
+46.2%
3-year compound annual growth
+24.8%
5-year compound annual growth
+14.8%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $10.78M | +37.5% | 2026-03-25, From 2025-01-01 |
| 2024-12-31 | $7.84M | +94.7% | 2026-03-25, From 2024-01-01 |
| 2023-12-31 | $4.03M | +16.8% | 2025-03-25, From 2023-01-01 |
| 2022-12-31 | $3.45M | -35.5% | 2024-03-25, From 2022-01-01 |
| 2021-12-31 | $5.35M | +50.0% | 2023-03-23, From 2021-01-01 |
| 2020-12-31 | $3.57M | -33.8% | 2022-07-07, From 2020-01-01 |
| 2019-12-31 | $5.39M | -33.1% | 2021-03-25, From 2019-01-01 |
| 2018-12-31 | $8.06M | -22.0% | 2020-03-04, From 2018-01-01 |
| 2017-12-31 | $10.33M | +22.7% | 2019-03-01, From 2017-01-01 |
| 2016-12-31 | $8.42M | +210.0% | 2018-03-02, From 2016-01-01 |
| 2015-12-31 | $2.72M | +411.6% | 2017-02-23, From 2015-01-01 |
| 2014-12-31 | $531.1K | n/a | 2016-03-30, From 2014-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Kiora Pharmaceuticals Inc (KPRX) | 2025-12-31 | $10.78M | +37.5% |
| Abbott Laboratories (ABT) | 2025-12-31 | $2.94B | +3.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $9.95B | -10.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $13.34B | +21.3% |
| Pfizer Inc (PFE) | 2025-12-31 | $10.44B | -3.6% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $14.66B | -14.9% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $1.90M | +11.8% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $15.79B | -12.0% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $1.90M | -7.5% |
Compare KPRX, ABT, BMY, LLY side by side · Screen every company in Pharmaceutical Preparations ↗